David H. Kirske Net Worth

The estimated Net Worth of David Kirske is at least $913 Tisíc dollars as of 29 December 2022. Mr Kirske owns over 54,042 units of CTI BioPharma Corp stock worth over $401,305 and over the last 7 years he sold CTIC stock worth over $0. In addition, he makes $511,736 as Exec. VP a CFO & Sec. at CTI BioPharma Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Kirske CTIC stock SEC Form 4 insiders trading

Mr has made over 6 trades of the CTI BioPharma Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 54,042 units of CTIC stock worth $51,340 on 29 December 2022.

The largest trade he's ever made was exercising 141,041 units of CTI BioPharma Corp stock on 29 September 2022 worth over $133,989. On average, Mr trades about 18,112 units every 12 days since 2017. As of 29 December 2022 he still owns at least 44,148 units of CTI BioPharma Corp stock.

You can see the complete history of Mr Kirske stock trades at the bottom of the page.

Mr. David H. Kirske biography

David H. Kirske is the Exec. VP, CFO & Sec. at CTI BioPharma Corp.

What is the salary of Mr Kirske?

As the Exec. VP a CFO & Sec. of CTI BioPharma Corp, the total compensation of Mr Kirske at CTI BioPharma Corp is $511,736. There are 3 executives at CTI BioPharma Corp getting paid more, with Dr. Adam R. Craig having the highest compensation of $1,031,430.

How old is Mr Kirske?

Mr Kirske is 67, he's been the Exec. VP a CFO & Sec. of CTI BioPharma Corp since . There are 1 older and 4 younger executives at CTI BioPharma Corp. The oldest executive at CTI BioPharma Corp is Bruce K. Bennett Jr., 69, who is the Sr. VP Global Pharmaceutical Operations.

What's Mr Kirske's mailing address?

David's mailing address filed with the SEC is 3101 WESTERN AVENUE, SUITE 800, , SEATTLE, WA, 98121.

Insiders trading at CTI BioPharma Corp

Over the last 21 years, insiders at CTI BioPharma Corp have traded over $80,110,449 worth of CTI BioPharma Corp stock and bought 9,566,060 units worth $25,487,533 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Advisors Llc Orbi Med Capit.... On average, CTI BioPharma Corp executives and independent directors trade stock every 26 days with the average trade being worth of $1,223,687. The most recent stock trade was executed by Adam R Craig on 24 January 2023, trading 85,317 units of CTIC stock currently worth $71,666.

What does CTI BioPharma Corp do?

cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.

Complete history of Mr Kirske stock trades at CTI BioPharma Corp

CTI BioPharma Corp executives and stock owners

CTI BioPharma Corp executives and other stock owners filed with the SEC include:

• Dr. Adam R. Craig,
  Pres, CEO, Interim Chief Medical Officer & Director
• Dr. Adam R. Craig M.B.A., M.D., Ph.D.,
  Pres, CEO, Interim Chief Medical Officer & Director
• Bruce J. Seeley,
  Exec. VP & COO
• David H. Kirske,
  Exec. VP, CFO & Sec.
• James K. Fong,
  Sr. VP & Chief Commercial Officer
• Dr. Jennifer A. Smith,
  Sr. VP of Biometrics
• John Volpone,
  Sr. VP of Strategic Operations
• Bruce K. Bennett Jr.,
  Sr. VP Global Pharmaceutical Operations
• Jim Fong,
  Sr. VP of US Commercial Operations
• Ed Bell,
  Sr. Director of Investor Relations
• Partners L P/Ilbiotechnolog...,
  
• Fred Telling,
  Director
• Reed Vaughn Tuckson,
  Director
• Michael A Metzger,
  Director
• Richard L Love,
  Director
• David Ross Parkinson,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Matthew D Perry,
  Director
• Phillip M Phd Nudelman,
  Director
• Matthew Plunkett,
  EVP, Corporate Development
• Healthcare Sabaxter Interna...,
  
• Steven E Benner,
  EVP, Chief Medical Officer
• James K Fong,
  EVP & Chief Commercial Officer
• Laurent Fischer,
  Director
• Bruce J. Seeley,
  EVP, Chief Operating Officer
• Partners L P/Ilbiotechnolog...,
  
• Adam R Craig,
  President and CEO
• Jack W Singer,
  EVP, Research Program Chairman
• David Kirske,
  EVP, Chief Financial Officer
• Craig Philips,
  President
• Daniel G Eramian,
  EVP, Corporate Communications
• Jade Brown,
  EVP, Chief Business Officer
• James Canfield,
  Chief Administrative Officer
• Max Link,
  Director
• Louis A Bianco,
  EVP, Finance & Administration
• Erich Platzer,
  Director
• Richard Jr Leigh,
  Exec. V.P., General Counsel
• James A Bianco,
  President and CEO
• Jack L Bowman,
  Director
• Scott Stromatt,
  EVP, Clinical Dev & Reg Affair
• Steve Aselage,
  EVP, Global Commercial Ops
• Edward F Kenney,
  EVP, Chief Operating Officer
• Martin P Sutter,
  Director
• John M Jr Fluke,
  Director
• Silvano Spinelli,
  EVP, Development
• Mary Oneil Mundinger,
  Director
• John H Bauer,
  Director
• Karen Ignagni,
  Director
• Vartan Gregorian,
  Director
• Healthcare Sa Baxter,
  10% owner
• Diane L. Parks,
  Director
• Advisors Llc Orbi Med Capit...,